bcr-abl (b3a2)-derived peptide vaccine

Definition / meaning of bcr-abl (b3a2)-derived peptide vaccine

A peptide vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein.Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a ‘b3a2’ or a ‘b2a2’ fusion.

Listed under:

Find More About 'bcr-abl (b3a2)-derived peptide vaccine'


The Web site of the National Cancer Institute (http://www.cancer.gov/)

Leave a Comment


This site uses Akismet to reduce spam. Learn how your comment data is processed.